Investor Samsara BioCapital, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Samsara BioCapital, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-09-03 13D/A VTVT / vTv Therapeutics Inc. 265,620 343,223
2025-08-14 13G/A LPTX / Leap Therapeutics, Inc. 2,442,352 0
2025-08-14 13G/A OKUR / OnKure Therapeutics, Inc. 824,155 0
2025-08-14 13G/A PVLA / Palvella Therapeutics, Inc. 679,486 339,743
2025-05-23 13D/A ALMS / Alumis Inc. 4,801,370
2025-03-27 13D/A SYRS / Syros Pharmaceuticals, Inc. 2,515,523 707,114
2025-03-25 13D KLRS / Kalaris Therapeutics, Inc. 11,448,081
2025-03-17 13D/A MLYS / Mineralys Therapeutics, Inc. 5,092,027 5,736,305
2025-02-14 13G/A IOBT / IO Biotech, Inc. 3,640,015 2,631,578
2024-12-20 13G PVLA / Palvella Therapeutics, Inc. 679,486
2024-11-27 13G/A NGNE / Neurogene Inc. 1,282,563 1,717,127
2024-11-14 13G/A LYRA / Lyra Therapeutics, Inc. 2,780,261 3,281,766
2024-11-14 13G/A CRGX / CARGO Therapeutics, Inc. 4,121,689 4,415,689
2024-11-04 13G SEPN / Septerna, Inc. 2,768,520
2024-10-11 13G OKUR / OnKure Therapeutics, Inc. 824,155
2024-10-07 13D/A SRRK / Scholar Rock Holding Corporation 7,878,302 6,757,255
2024-08-27 13D 3,266,498
2024-04-25 13G LPTX / Leap Therapeutics, Inc. 2,442,352
2024-03-29 13D/A NKTX / Nkarta, Inc. 2,868,035 3,768,035
2024-03-25 13G/A LENZ / LENZ Therapeutics, Inc. 8,497,067 1,213,865
2024-03-05 13D VTVT / vTv Therapeutics Inc. 265,620
2024-02-14 13G/A RAIN / Rain Enhancement Technologies Holdco, Inc. 2,260,652 0
2024-02-14 13G NGNE / Neurogene Inc. 1,282,563
2024-02-12 13D/A MLYS / Mineralys Therapeutics, Inc. 4,521,805 5,092,027
2023-12-26 13D/A SYRS / Syros Pharmaceuticals, Inc. 1,605,546 2,515,523
2023-12-18 13G IOBT / IO Biotech, Inc. 3,640,015
2023-11-22 13D/A KDNY / Chinook Therapeutics Inc 5,181,557 0
2023-11-21 13G CRGX / CARGO Therapeutics, Inc. 4,121,689
2023-10-20 13D SYRS / Syros Pharmaceuticals, Inc. 1,605,546
2023-10-18 13D/A SRRK / Scholar Rock Holding Corporation 5,676,076 7,878,302
2023-08-25 13G LYRA / Lyra Therapeutics, Inc. 2,780,261
2023-02-24 13D MLYS / Mineralys Therapeutics, Inc. 4,521,805
2023-02-14 13D SRRK / Scholar Rock Holding Corporation 5,676,076
2023-02-14 13G/A GRPH / Graphite Bio, Inc. 7,851,933 8,497,067
2023-02-14 13G RAIN / Rain Enhancement Technologies Holdco, Inc. 2,260,652
2023-02-14 13D/A NKTX / Nkarta, Inc. 2,034,703 2,868,035
2022-06-01 13D KDNY / Chinook Therapeutics Inc 5,181,557
2022-02-14 13G/A GRPH / Graphite Bio, Inc. 7,431,623 7,851,933
2021-07-09 13G GRPH / Graphite Bio, Inc. 7,431,623
2020-07-22 13D NKTX / Nkarta, Inc. 2,034,703
2020-03-06 13G ACRS / Aclaris Therapeutics, Inc. 2,161,333
2020-03-05 13G 867328601 / Sunesis Pharmaceuticals, Inc. 5,938,215